Q-omics provides the consensus-scored RPSAP75 profile across patient tissues and cancer cell-line models. RPSAP75 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPSAP75 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, RPSAP75 RNA expression shows 9,640 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRP, and GBM as cancer lineages where RPSAP75 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP75 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP75 survival associations across molecular data types. RPSAP75 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP75 RNA expression–survival associations across cancer types. High RPSAP75 expression shows unfavorable associations in LUAD, ACC, UVM, KIRC and THCA, but favorable associations in OV. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for RPSAP75 RNA expression.
This table summarizes RPSAP75 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP75. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP75 shows lower tumor expression in KIRP, KIRC, READ, COAD and BRCA and higher tumor expression in LIHC. The KIRP box plot shows higher RPSAP75 RNA expression in normal versus tumor tissue (log2 FC = −0.205, t-test p < 0.001).
This table shows molecular features associated with RPSAP75 in patient tissues and cancer cell lines. In patient samples, RPSAP75 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
